Elicio Therapeutics, Inc. Lease, Cost
Elicio Therapeutics, Inc. (ELTX) reported Lease, Cost of $27.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2023-05-10
- Elicio Therapeutics, Inc. lease, cost for the quarter ending 2023-03-31 was $27.00K, a 94.27% decline year-over-year.
- Elicio Therapeutics, Inc. lease, cost for the quarter ending 2022-12-31 was $400.00K, a 1.23% decline year-over-year.
- Elicio Therapeutics, Inc. lease, cost for the quarter ending 2022-09-30 was $415.00K, a 1.72% increase year-over-year.
- Elicio Therapeutics, Inc. lease, cost for the quarter ending 2022-06-30 was $399.00K, a 1.48% decline year-over-year.
- Elicio Therapeutics, Inc. lease, cost for fiscal 2022 was $1.69M, a 1.57% increase from fiscal 2021.
- Elicio Therapeutics, Inc. lease, cost for fiscal 2021 was $1.66M, a 9.64% decline from fiscal 2020.
- Elicio Therapeutics, Inc. lease, cost for fiscal 2020 was $1.84M.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-03-31 | $27.00K 10-Q · filed 2023-05-10 | $427.00K derived: sum of 2 quarters · filed 2023-05-10 | $842.00K derived: sum of 3 quarters · filed 2023-05-10 | $1.24M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $815.00K derived: sum of 2 quarters · filed 2023-03-17 | $1.21M derived: sum of 3 quarters · filed 2023-03-17 | $1.69M 10-K · filed 2023-03-17 |
| 2022-09-30 | $415.00K 10-Q · filed 2022-11-14 | $814.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.28M 10-Q · filed 2022-11-14 | $1.69M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-06-30 | $399.00K 10-Q · filed 2022-08-15 | $870.00K 10-Q · filed 2022-08-15 | $1.27M derived: sum of 3 quarters · filed 2023-05-10 | $1.68M derived: sum of 4 quarters · filed 2023-05-10 |
| 2022-03-31 | $471.00K 10-Q · filed 2023-05-10 | $876.00K derived: sum of 2 quarters · filed 2023-05-10 | $1.28M derived: sum of 3 quarters · filed 2023-05-10 | $1.69M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $405.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $813.00K derived: sum of 2 quarters · filed 2023-03-17 | $1.22M derived: sum of 3 quarters · filed 2023-03-17 | $1.66M 10-K · filed 2023-03-17 |
| 2021-09-30 | $408.00K 10-Q · filed 2022-11-14 | $813.00K derived: sum of 2 quarters · filed 2022-11-14 | $1.25M 10-Q · filed 2022-11-14 | $1.68M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $405.00K 10-Q · filed 2022-08-15 | $847.00K 10-Q · filed 2022-08-15 | $1.27M derived: sum of 3 quarters · filed 2022-08-15 | $1.89M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $442.00K 10-Q · filed 2022-05-16 | $864.00K derived: sum of 2 quarters · filed 2022-05-16 | $1.48M derived: sum of 3 quarters · filed 2022-05-16 | $1.84M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $422.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $1.04M derived: sum of 2 quarters · filed 2022-03-30 | $1.40M derived: sum of 3 quarters · filed 2022-03-30 | $1.84M 10-K · filed 2022-03-30 |
| 2020-09-30 | $620.00K 10-Q · filed 2021-11-12 | $973.00K derived: sum of 2 quarters · filed 2021-11-12 | $1.41M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $353.00K 10-Q · filed 2021-08-12 | $794.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $441.00K 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |